Guideline Recommendations for Dementia with Lewy Bodies

Pharmacologic Management – Cognitive and Neuropsychiatric Symptoms

Cholinesterase inhibitors (e.g., rivastigmine, donepezil) are recommended as first‑line therapy to improve cognition and neuropsychiatric manifestations such as visual hallucinations in DLB. 1
Rivastigmine has the strongest evidence base for DLB, showing efficacy across multiple domains; the transdermal patch improves tolerability. 2
Memantine may be added for patients with moderate‑to‑severe DLB when cholinesterase inhibition alone is insufficient; evidence is limited but suggests benefit. 3
Licensed agents (donepezil, rivastigmine, galantamine, memantine) provide a temporary reduction or slowing of cognitive decline but are not disease‑curative. 4

High‑quality, person‑centered and psychosocial interventions should be the initial approach for behavioral and psychological symptoms; pharmacologic treatment is reserved for short‑term, carefully monitored use. 4
Antipsychotic medications should be avoided whenever possible because DLB patients have a markedly increased risk of severe adverse events—including falls, stroke, and neuroleptic‑sensitivity reactions. 1

Rapid‑eye‑movement sleep behavior disorder (RBD) in DLB should be treated first‑line with clonazepam or immediate‑release melatonin (American Academy of Sleep Medicine). 5
Transdermal rivastigmine can be considered for RBD in DLB patients with mild cognitive impairment, offering concurrent benefits for cognition and sleep. 5

Cognitive stimulation therapy delivered in small groups is recommended for mild‑to‑moderate DLB to target orientation, concentration, and memory. 6
Structured psychoeducational and psychosocial programs for caregivers—including education, counseling, skill‑building, and problem‑solving—are essential components of care. 6
Case management improves coordination and continuity of care for individuals with DLB. 6
Creating dementia‑friendly environments that address visual‑spatial deficits and fluctuating cognition enhances safety and quality of life. 6

Medications with anticholinergic properties must be avoided, as they exacerbate cognitive impairment and can precipitate delirium. 7
Before modifying dementia‑specific medications, clinicians should systematically rule out delirium secondary to infection, metabolic disturbances, stroke, or depression. 7

Regular reassessment of cognitive, functional, neuropsychiatric, and behavioral status is required during pharmacologic treatment to gauge disease progression and adjust therapy. 3
Patients with DLB need more frequent follow‑up than those with other dementias because of symptom fluctuations and the complexity of medication regimens. 7

The choice of a specific cholinesterase inhibitor for Lewy body dementia should be guided by tolerability, adverse‑effect profile, ease of use, and medication cost, because current evidence does not definitively demonstrate superiority of one agent over another. 8